Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.80 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.80 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.80 |
| ▸ | PGR | P06401 | 1/20 | 0.80 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.75 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.75 |
| ▸ | TSHR | P16473 | 1/20 | 0.75 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | PPARG | P37231 | 3/20 | 0.60 |
| ▸ | OXER1 | Q8TDS5 | 3/20 | 0.60 |
| ▸ | RXRA | P19793 | 2/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.60 |
| ▸ | F7 | P08709 | 3/20 | 0.52 |
| ▸ | F3 | P13726 | 3/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4984694 | 1.00 | ADORA3 (0.80) | ADORA3NR1I2PTGS2PGRPDE4D | |
| SCHEMBL4425859 | 1.00 | ADORA3 (0.80) | ADORA3NR1I2PTGS2PGRPDE4D | |
| SCHEMBL15130626 | 1.00 | ADORA3 (0.80) | ADORA3NR1I2PTGS2PGRPDE4D | |
| SCHEMBL4984691 | 1.00 | ADORA3 (0.80) | ADORA3NR1I2PTGS2PGRPDE4D | |
| SCHEMBL16994601 | 0.94 | ADORA3 (0.70) | ADORA3NR1I2PTGS2PGRPDE4D | |
| SCHEMBL11467652 | 0.94 | ADORA3 (0.70) | ADORA3NR1I2PTGS2PGRPDE4D | |
| SCHEMBL11467654 | 0.94 | ADORA3 (0.70) | ADORA3NR1I2PTGS2PGRPDE4D | |
| Icosapent Ethyl SCHEMBL29356075 | 0.93 | ADORA3 (0.93) | ADORA3NR1I2PTGS2PGRPDE4D | |
| SCHEMBL21734038 | 0.92 | ADORA3 (0.69) | ADORA3NR1I2PTGS2PGRPDE4D | |
| Icosapent Ethyl SCHEMBL119168 | 0.89 | ADORA3 (1.00) | ADORA3NR1I2PTGS2PGRPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000632-A1 | STRUCTURALLY MODIFIED FATTY ACIDS FOR IMPROVING GLYCEMIC CONTROL AND TREATING INFLAMMATORY BOWEL DISEASE | NORTHSEA THERAPEUTICS B V (NL) | 2026-01-01 | — | — | US | disclosed |
| EP-4619001-A1 | ORAL DOSAGE FORMS FOR THE TREATMENT OF LIVER DISORDERS AND METHODS OF PREPARING THE SAME | Viking Therapeutics, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250223253-A1 | SITE-SPECIFIC ISOTOPIC LABELING OF 1,4-DIENE SYSTEMS | BIOJIVA LLC (US) | 2025-07-10 | — | — | US | disclosed |
| US-20250134913-A1 | ORAL DOSAGE FORMS OF TRβ AGONIST VK2809 FOR THE TREATMENT OF LIVER DISORDERS AND METHODS OF PREPARING THE SAME | VIKING THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4482470-A1 | CYCLIC PHOSPHONATE COMPOSITION AND PREPARATION METHOD THEREOF | Gannex Pharma Co., Ltd. (CN) | 2025-01-01 | — | — | EP | disclosed |
| EP-4479062-A1 | FORMES POSOLOGIQUES ORALES DE L'AGONISTE DE TRß, VK2809, POUR LE TRAITEMENT DE TROUBLES HÉPATIQUES, ET PROCÉDÉS DE PRÉPARATION DE CELLES-CI | Viking Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| CN-119072316-A | Oral dosage forms of TR beta agonist VK2809 for treating liver disorders and methods of preparing the same | 维京治疗公司 | 2024-12-03 | — | — | CN | disclosed |
| US-20240325417-A1 | COMBINATION THERAPY FOR TREATMENT OF LIVER DISEASES | GANNEX PHARMA CO., LTD. (CN) | 2024-10-03 | — | — | US | disclosed |
| US-20240293385-A1 | COMBINATION THERAPY FOR TREATMENT OF LIVER DISEASES | GANNEX PHARMA CO., LTD. (CN) | 2024-09-05 | — | — | US | disclosed |
| US-12060324-B2 | Site-specific isotopic labeling of 1,4-diene systems | BIOJIVA LLC (US) | 2024-08-13 | — | — | US | disclosed |
| US-7550613-B2 | alpha-methoxy docosahexanoic acid ethyl ester, alpha-iodo-docosahexanoic acid ethyl ester; antidiabetic for diabetes type 2, cardiovascular disorders, obesity, amyloidosis, prophylaxis; free of 4,7,10,13,16,19-docosahexanoic acid ( DHA), alpha-methyl DHA, alpha-methyl DHA-methyl ester | PRONOVA BIOPHARMA NORGE AS (NO) | 2009-06-23 | — | — | US | disclosed |
| US-20080300306-A1 | Novel Compounds | BRYHN MORTEN | 2008-12-04 | — | — | US | disclosed |
| US-20080300306-A1 | Novel Compounds | BRYHN MORTEN | 2008-12-04 | — | — | US | disclosed |
| WO-2008113177-A1 | COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF | CENTRE DE RECHERCHE SUR LES BIOTECHNOLOGIES MARINES (CA) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008098375-A1 | POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF | CENTRE DE RECHERCHE SUR LES BIOTECHNOLOGIES MARINES (CA) | 2008-08-21 | — | — | WO | disclosed |
| US-20070088170-A1 | Novel compounds | PRONOVA BIOPHARMA NORGE AS (NO) | 2007-04-19 | — | — | US | disclosed |
| US-20070088170-A1 | Novel compounds | PRONOVA BIOPHARMA NORGE AS (NO) | 2007-04-19 | — | — | US | disclosed |
| EP-1392621-A2 | SOLID PHASE EXTRACTION METHOD FOR OBTAINING HIGH-PURITY UNSATURATED COMPOUNDS OR DERIVATIVES OF SAID COMPOUNDS | Nutrinova Nutrition Specialties & Food Ingredients GmbH (DE) | 2004-03-03 | — | — | EP | disclosed |
| US-20030175914-A1 | Method for producing glycerides of conjugated, polyunsaturated fatty acids on the basis of their alkyl esters | BASF AKTIENGESELLSCHAFT (DE) | 2003-09-18 | — | — | US | disclosed |
| WO-2002098826-A2 | SOLID PHASE EXTRACTION METHOD FOR ISOLATING UNSATURATED COMPOUNDS | NUTRINOVA NUTRITION SPECIALTIES & FOOD INGREDIENTS GMBH (DE) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12060324-B2 | Site-specific isotopic labeling of 1,4-diene systems | FADS1, FASN, FADS2 | ADORA3 1889/4885NR1I2 1199/4885PTGS2 1250/4885 |
| US-20260000632-A1 | STRUCTURALLY MODIFIED FATTY ACIDS FOR IMPROVING GLYCEMIC CONTROL AND TREATING INFLAMMATORY BOWEL DISEASE | GLP1R, FFAR3, IAPP | ADORA3 734/4885NR1I2 3490/4885PTGS2 386/4885 |
| US-20070088170-A1 | Novel compounds | FFAR2, GPR119, ALOX12 | ADORA3 756/4885NR1I2 273/4885PTGS2 334/4885 |
| US-20240325417-A1 | COMBINATION THERAPY FOR TREATMENT OF LIVER DISEASES | PYGL, GYS2, OAT | ADORA3 3205/4885NR1I2 294/4885PTGS2 1455/4885 |
| US-20250223253-A1 | SITE-SPECIFIC ISOTOPIC LABELING OF 1,4-DIENE SYSTEMS | FADS1, FASN, FADS2 | ADORA3 1889/4885NR1I2 1199/4885PTGS2 1250/4885 |
| US-20080300306-A1 | Novel Compounds | GPR119, FFAR2, ALOX12 | ADORA3 730/4885NR1I2 288/4885PTGS2 371/4885 |
| US-20250134913-A1 | ORAL DOSAGE FORMS OF TRβ AGONIST VK2809 FOR THE TREATMENT OF LIVER DISORDERS AND METHODS OF PREPARING THE SAME | AVPR1A, THRA, PRLHR | ADORA3 1156/4885NR1I2 143/4885PTGS2 2136/4885 |
| US-20240293385-A1 | COMBINATION THERAPY FOR TREATMENT OF LIVER DISEASES | SLC10A1, OAT, GOT2 | ADORA3 2341/4885NR1I2 134/4885PTGS2 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.